Bivalent inactivated vaccine for bovine multocida pasteurellosis and preparation method of bivalent inactivated vaccine

A bivalent inactivated vaccine, Pasteurella technology, applied in blood diseases, antibacterial drugs, pharmaceutical formulations, etc., can solve the problem of poor cross immunity, difficult prevention and control of bovine pasteurellosis multocida Control cattle fibrinous purulent pneumonia and other problems to achieve the effect of reducing side effects, good immune protection effect, and reducing bacterial exotoxin content

Active Publication Date: 2018-01-12
HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI +1
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In view of the poor cross immunity between different serotypes of Pasteurella multocida, the existing commercial products cannot effectively prevent and control the bovine fibrinous suppurative pneumonia caused by capsular type A bacteria, and give cattle Pasteurella multocida disease The prevention and control of the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bivalent inactivated vaccine for bovine multocida pasteurellosis and preparation method of bivalent inactivated vaccine
  • Bivalent inactivated vaccine for bovine multocida pasteurellosis and preparation method of bivalent inactivated vaccine
  • Bivalent inactivated vaccine for bovine multocida pasteurellosis and preparation method of bivalent inactivated vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Preparation of Bivalent Inactivated Vaccine for Bovine Pasteurella Multocida

[0031] 1. Medium

[0032] Preparation of Brain Heart Infusion Medium (BHI): Weigh 37g of BHI powder and add it to 1000ml of distilled water, mix thoroughly, and then sterilize at 121°C for 15 minutes.

[0033] Preparation of Martin Broth Medium: Weigh 50g of Martin Broth Medium Powder and add it to 1000ml of distilled water. After mixing thoroughly, sterilize at 121°C for 15 minutes. After sterilization, add 0.1% lysed hemocyte whole blood according to the volume of the medium.

[0034] Brain Heart Infusion Agar Medium Preparation: Weigh 37g of BHI powder and 15g of agar powder into 1000ml of distilled water, mix thoroughly, sterilize at 121°C for 15 minutes, cool to 50°C to 60°C, pour the plates for later use.

[0035] Preparation of Martin Broth Agar Medium: Weigh 50g of Martin Broth Medium Powder and 15g of Agar Powder into 1000ml of distilled water, mix well, sterilize at 121°C...

Embodiment 2

[0055] Example 2 The safety test of the vaccine prepared by the present invention

[0056] 1 material

[0057] The vaccine that the method for 1.1 embodiment 1 makes bovine pasteurellosis multocida bivalent inactivated vaccine (A type Pm-TJ strain+B type C45-2 strain). The batch numbers are ZM201401, ZM201402, ZM201403 respectively.

[0058] 1.2 Experimental animals Healthy susceptible cattle, 3 months old and above.

[0059] 2 methods

[0060] 2.1 Safety test of a single-dose inoculation of target animals

[0061] 12 test cows were randomly divided into four groups, and 3 batches of vaccines were inoculated through the neck muscles with a single dose of 2.0ml (1 head), and 3 test cows with the same conditions were set up. Cattle were inoculated with sterilized PBS as a control in the same way. The clinical manifestations of the test cattle were observed, and the body temperature was measured at the same time every day for 14 days.

[0062] 2.2 Safety test of single-dose...

Embodiment 3

[0082] Example 3 Efficacy Test of the Vaccine Prepared by the Present Invention

[0083] 1 material

[0084] 1.1 The vaccine made by the method of Example 1 Bovine Pasteurella multocida bivalent inactivated vaccine (A type Pm-TJ strain+B type C45-2 strain). The batch numbers are ZM201401, ZM201402, ZM201403 respectively. The batch number of inactivated bovine pasteurellosis multocida vaccine (type B strain single vaccine, C45-2 strain, C46-2 strain, and C47-2 strain all contains) is 1407001.

[0085] 1.2 The experimental animals are healthy and susceptible cattle, aged 6 months and above.

[0086] 2 methods

[0087] 3 batches of vaccines prepared by the present invention were inoculated into 8 test cows with 1 part (2.0ml) dose each muscle, and the commercially available bovine pasteurellosis multocida inactivated vaccine (type B bacteria single vaccine) was injected with 1 cow. Each dose (4.0ml) was intramuscularly inoculated to 4 test cows, and another 6 non-immunized co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to a bivalent inactivated vaccine for bovine multocida pasteurellosis, belonging to the technical field of preparation of veterinary biological products. The bivalent inactivatedvaccine provided by the invention is composed of antigens and a vaccine adjuvant, wherein the antigens are a bovine multocida pasteurellosis capsular type-A Pm-TJ strain and a bovine multocida pasteurellosis capsular type-B C45-2 strain. For the bivalent inactivated vaccine prepared by adopting the method provided by the invention, the concentration purifying process is adopted, the fermentationculture process of the bovine multocida pasteurellosis capsular type-B C45-2 strain is optimized, so that the fermentation time is shortened by one half, and the production efficiency is improved. Forthe bivalent inactivated vaccine provided by the invention, the bovine fibrinous and suppurative pneumonia and bovine hemorrhagic septicemia caused by bovine pasteurella multocida infection can be prevented through one-time injection immunization, and the bivalent inactivated vaccine has the features of safety, reliability and good immune effect.

Description

technical field [0001] The invention belongs to the technical field of veterinary biological products, and in particular relates to a bivalent inactivated vaccine against pasteurellosis multocida. Background technique [0002] Bovine Pasteurella multocida is an infectious disease caused by Pasteurella multocida infection in cattle. At present, there are mainly two types of Pasteurella multocida prevailing in my country, one is bovine fibrinous suppurative pneumonia caused by Pasteurella multocida capsule type A bacteria, and the other is caused by Pasteurella multocida capsule type A bacteria, and the other is caused by Pasteurella multocida capsule type A bacteria, Hemorrhagic septicemia in cattle caused by Pasteurella spp. capsulatus type B. Among them, bovine fibrinous suppurative pneumonia is a disease that seriously infringes on the respiratory system of cattle. Under the stimulation of stress conditions such as long-distance transportation after healthy cattle are mixe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/116A61K39/102A61P31/04A61P7/04A61P11/00
Inventor 徐和敏姜志刚邵葳于力潘春刚张爱民罗显绎姜晓红马爱荣周建民
Owner HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products